








































































































Can Cognitive Remediation in Groups Prevent Relapses?
Results of a 1-Year Follow-up Randomized Controlled Trial
Daniel R. Mueller, PhD,* Zahra Khalesi, BSc,*† and Volker Roder, PhD*
Abstract: International guidelines define relapse prevention for schizophrenia
patients as a key therapeutic aim. However, approximately 80% to 90% of schizo-
phrenia patients experience further symptom exacerbation after the first episode.
The purpose of this study was to investigate whether group integrated neurocog-
nitive therapy (INT), a cognitive remediation approach, reduces relapse rates in
schizophrenia outpatients. INTwas compared with treatment as usual (TAU) in
a randomized controlled trial. Fifty-eight stabilized outpatients participated in
the study with 32 allocated to the INT group and 26 to the TAU group. A test battery
was used at baseline, posttreatment at 15weeks, and a 1-year follow-up. Relapse rates
were significantly lower in the INT condition compared with TAU during therapy as
well as at follow-up. The relapse rate after therapywas associatedwith significant
reductions in negative and general symptoms, improvements in functional outcome,
and overall cognition. Out of these variables, negative symptoms were identified to
show the strongest association with relapses after therapy. The primary outcome of
this study suggests that INT can prevent relapses in schizophrenia outpatients.
KeyWords: Schizophrenia, RCT, psychological therapy, cognitive remediation,
group therapy, relapse prevention
(J Nerv Ment Dis 2020;208: 362–370)
S chizophrenia is a chronic and debilitating illness that is associatedwith reduced functioning and overall quality of life (Khalesi et al.,
2019; Strauss et al., 2010). The majority of patients experience multiple
relapses throughout the course of the illness, whereas only 10% to 20%
of patients never have a recurrent episode after their first psychosis episode
(Emsley et al., 2013). The resurgence of symptoms after stabilization is
often referred to as a relapse. Such relapses can be associated with progres-
sive functional deterioration, a decline in treatment response, worsening
clinical outcomes, increasing caregiver burden, and an increased economic
burden for families, society, and healthcare systems (Alphs et al., 2016;
Pennington and McCrone, 2017; Rosenberg, 2009).
Many factors can contribute to symptom relapse. Antipsychotic
medication has been shown to reduce relapses compared with placebo
(Leucht et al., 2012); however, many patients with schizophrenia have
trouble adhering to medication, which is ultimately a risk factor for relapse
and a strong factor for overall recovery (Kane et al., 2018; Kishimoto et al.,
2013). Although there are many dimensions to “recovery” (Roder et al.,
2019;Whitley and Drake, 2010; Windell et al., 2012), symptom relapse
remains a germane component of recovery. The discontinuation or re-
duction of antipsychotic medication seems to be the most common risk
factor for relapse. Studies have revealed that approximately 50% of pa-
tients are not compliant with their medications, where the risk of re-
lapse increases from 20% to 30% to 60% to 80% when patients do
not take their medication consistently (Kane et al., 2018; Rosenberg,
2009). In fact, medication incompliance in first-episode patients leads
to symptom resurgence between 41% and 79% within 12 months after
a single episode and the likelihood of relapse increases to 96% after
24 months of medication incompliance (Emsley et al., 2013; Zipursky
et al., 2014). As such, relapse prevention is at the forefront of goals to
treatment response and recovery (Tibbo et al., 2014).
Given the personal, emotional, and economical costs associated
with symptom relapse, it is important to delineate which additional inter-
ventions, besides medication, provide evidence for relapse prevention.
There is a controversy about the efficacy of psychosocial interventions
for relapse prevention in schizophrenia. The use of psychosocial inter-
ventions has shown effective reductions of relapse rates for some psycho-
logical treatments (e.g., Jones et al., 2012; Pharoah et al., 2010; Xia et al.,
2011). Specifically, studies using manualized psychoeducation programs
and family therapy have demonstrated the strongest impact on relapse
prevention up to 1-year follow-up (Pharoah et al., 2010; Xia et al.,
2011). Relatively few studies have been conducted examining the effi-
cacy of other psychological interventions, such as cognitive behavioral
therapy for psychosis and social skills training (SST), on relapse preven-
tion (e.g., Jones et al., 2012; Kurtz andMueser, 2008; Naeem et al., 2016;
Revell et al., 2015; Turner et al., 2018).
Some studies have examined the impact of cognitive remediation
(CR) therapy approaches for relapse prevention (e.g., Kurtz et al., 2016;
Trapp et al., 2013;Wykes et al., 2011). The CR effects on positive symp-
toms were generally described as small (McGurk et al., 2007) and as
small to moderate regarding negative symptoms (Cella et al., 2017).
These low effects may be in line with previous literature suggesting that
positive symptoms may be independent of cognition and functioning
(Green and Nuechterlein, 1999; Roder and Mueller, 2015). That said,
there is evidence supporting an indirect association of cognition and re-
lapse. Cognition is related to treatment adherence and therapeutic alliance,
which is ultimately related to relapse rates (Alphs et al., 2016; Cella and
Wykes, 2019; Higashi et al., 2013). The studies mentioned previously
mainly used bottom-up neurocognitive training that utilize computer pro-
grams to improve basic neurocognitive domains (e.g., attention, memory),
which can have limited generalization effects. These interventions tend to
have minimal emphasis on the therapeutic relationship, group interactions,
and other variables of cognition (such as facets of social cognition in-
cluding perception and attribution). There are, however, some CR var-
iations and techniques that may help improve relapse rates. The
intervention we have used in this study incorporated both a bottom-up
and top-down approach that also builds on the therapeutic relationship,
group interactions, and other facets of cognition. This type of interven-
tion has previously shown a significant reduction of severe negative
symptoms (integrated neurocognitive therapy [INT]; Mueller et al.,
2017) and may have more generalizable effects in treatment response
than basic bottom-up CR approaches. In this approach, CR for neuro-
cognition is combined with CR for social cognition, a stress training
task, and an emotion regulation task similar to the tasks that can be
found in successful psychoeducation approaches for relapse preven-
tion. Consequently, CR approaches focusing on therapeutic alliance
and social cognition rather than only the use of computer programs,
combining neurocognitive and social cognitive rehabilitation with tasks
to regulate emotional stress experience, may potentiate their impact on
relapse prevention.
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Although relapse prevention is among the top goals for treat-
ment, it is often defined in different ways across studies (Csernansky
et al., 2002; Leucht, 2014; Olivares et al., 2013). The definition of a re-
lapse as an increase in symptom severity suggests that symptom remis-
sion is a primary goal of treatment. The Remission in Schizophrenia
Working Group (RSWG; Andreasen et al., 2005) created standardized
guidelines to evaluate remission in schizophrenia across studies. The
RSWGdefines remission as “a state in which patients have experienced
an improvement in core signs and symptoms to the extent that any re-
maining symptoms are of such low intensity that they no longer interfere
significantly with behavior and are below the threshold typically utilized
in justifying an initial diagnosis of schizophrenia” (Andreasen et al.,
2005). This definition relies on commonly used assessment instruments
such as diagnostic interview scales for a period of at least 6 months.
For example, the RSWG defines symptom remission, when measured
using the Positive and Negative Syndrome Scale (PANSS; Kay et al.,
1987), as mild symptom severity (≤3; range, 1–7) in 8 relevant items
out of the 30 PANSS items (for a detailed description, seeMethod later).
As such, a relapse can be defined as an increase of symptom severity ≥3
(≥mild symptom severity) at least in one of the defined items by RSWG.
The purpose of this study was to investigate whether a group CR
therapy, utilizing both bottom-up and top-down approaches, has an im-
pact on relapse prevention in stabilized schizophrenia outpatients. We
used INT (Roder and Mueller, 2015). We hypothesized that INT com-
bined with antipsychotic medication reduces relapses compared with
treatment as usual (TAU).
METHODS
Participants
A total of 58 patients with a diagnosis of schizophrenia or
schizoaffective disorder according to ICD-10 were recruited for this
study. The inclusion criteria for this study were the following: patients
referred from outpatient clinics had to have cognitive impairments iden-
tified, a cognitive battery was also completed at baseline before group
allocation; IQ scores of greater than or equal to 80 and were assessed
by the Reduced Wechsler Intelligence Test (Dahl, 1986); symptoms
were in remission for at least 2 months before study inclusion, as
assessed by their referring physician; finally, the age inclusion criteria
was between 18 and 50 years old. In addition, baseline PANSS (Kay
et al., 1987) assessments were conducted to confirm remission criteria
for a 2-week period defined by the RSWG (Andreasen et al., 2005).
The RSWG defined the criterion for symptom remission as mild symp-
tom severity (≤3; range, 1–7) in 8 of the 30 PANSS items a) positive
symptoms: delusions (P1), conceptual disorganization (P2), hallucina-
tory behavior (P3); b) negative symptoms: blunted affect (N1), social
withdrawal (N4), or lack of spontaneity (N6); and c) general symptoms:
mannerisms/posturing (G5), unusual thought content (G9). Exclusion
criteria for the outpatients in symptom remission were neurological dis-
orders, substance abuse according to ICD-10 within 6 months before
baseline assessments, and changes inmedication doseswithin 2 months
before baseline assessments.
All participants provided written informed consent before partic-
ipation under protocols approved by the ethics committee at the University
of Bern. After this procedure, a flowchart summarized the patient's
progress (Fig. 1). Participants were allocated to INT or TAU based on
a statistical randomization procedure by an independent statistician.
First, computer-generated random numbers were used to generate two
groups. Afterwards, these two groups were randomly assigned to INT
or TAU. Thirty-two patients were randomly assigned to the experimental
group (INT) and 26 patients to the control group (TAU). Four patients in
the INT condition and two patients in the TAU condition dropped out
during the 1-year assessment period. Two of the patients from the INT
group returned to competitivework that wasmaintained successfully dur-
ing the study period; the remaining two in the INTand two from the TAU
group either moved or could not be contacted for further assessments. For
these patients, no further information was available.
Procedure
The INT groups consisted of biweekly sessions (90 minutes
each) for 15 weeks with a total of 30 sessions. Five separate INT groups
composed of five to eight participants each were led by one main ther-
apist and one cotherapist. The main therapists, clinical psychologists,
were trained in cognitive and behavior therapy, and all had experience
FIGURE 1. Flow diagram of the RCT for the INT and TAU group.
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with CR interventions and group therapy. Treatment fidelity was controlled
by using a detailed protocol for the therapy sessions. A comprehensive
battery was administered for both INTand TAU groups at baseline (be-
fore randomization), posttreatment (ie, after 15 weeks), and after a
follow-up period of 9 months (1 year after baseline assessment).
Trained research assistants with an MSc degree carried out all assess-
ments; they were independent from the treatment and blind to
group allocation.
Intervention
INT is a manualized CRT group approach (Roder and Mueller,
2015). The treatment consists of all initially defined 11 neurocognitive
and social cognitive domains by the Measurement and Treatment Re-
search to Improve Cognition in Schizophrenia (MATRICS; Green
et al., 2005; Nuechterlein et al., 2004) of the National Institute of Men-
tal Health. These domains are divided into four therapy modules with
increasing complexity and emotional strain throughout the course of
therapy. Each module starts with interventions on neurocognitive
MATRICS domains followed by interventions on social cognition.
Each module focusing on a specific cognitive domain includes all four
components: first, define the respective cognitive domain and applies
the definition to the patient's real-life functioning; second, a compensa-
tion or learning part to develop the coping strategies; third, a restitution
or training part to practice the coping strategies using both group exer-
cises and computer-based exercises; and fourth, in vivo exercises are
administered. The final sessions of INT then focus on emotion regula-
tion and stress reduction tools. The control condition TAU was defined as
standard care including a broad array of interventions (e.g., medication,
individual therapy, case-management). Furthermore, all study partici-
pants were not allowed to take part in evidence-based group therapies
targeting cognitive outcomes, though were permitted to enroll in other
kinds of group interventions such as music therapy, art therapy, dance
therapy, psychoeducation, supportive and vocational counseling, and lei-
sure time-groups throughout the course of the study. It should be noted
that the TAU group likely received significantly less timewith healthcare
professionals due to the constraint of not enrolling in an active treatment
targeting cognitive symptoms, whereas the INT group received the bi-
weekly therapeutic sessions for 15 weeks.
Assessments
Symptoms
The PANSS (Kay et al., 1987) was the key assessment instru-
ment for this study. The whole PANSS interview was administered
for a 2-week period to rate negative, positive, and general symptom se-
verity. The 2-week period differed slightly from the standard instruction
recommending 1-week only. The reason for the longer observation pe-
riod was to improve the change sensitivity of the assessment. All
blinded raters received specific training and revealed high interrater
reliability (ICC = 0.91).
Functional Outcome
The Global Assessment of Functioning (GAF) scale of the
DSM-4 was used to measure functional outcome. GAF was adminis-
tered by the same independent and blinded raters as PANSS. Again,
the interrater reliability was high (ICC = 0.92).
Cognition
A broad array of assessments regarding cognitive functioning
was conducted: 1) speed of processing assessed using the Trail Making
Test, Part A (TMT; Reitan, 1958); 2) attention measured with the d2
task (Brickenkamp et al., 2010), which is a paper-and-pencil cancellation
test that has proven to be a reliable and valid measure of selective atten-
tion; 3) verbal learning and memory were assessed using the Auditory
Verbal Learning Test (AVLT), a delayed recognition memory task
(Lezak, 2004); 4) reasoning and problem solving was measured using
theWisconsin Card Sorting Test (WCST), number of perseverative errors
(Loong, 1989); 5) working memory measured with the Letter-Number
Span (LNS; Gold et al., 1997); 6) emotion perception assessed with the
Picture of Facial Affect (PFA) test (Frommann et al., 2003); and 7) the
Emotion Recognition Questionnaire (EMOREC; Bähler, 2012). Both
measures require the patients to view photographs of faces and to identify
specific basic emotions (PFA) or to rate the intensity of the perceived
emotion on a 5-point Likert scale (EMOREC); and 8) the Schema Com-
ponent Sequencing Task–Revised (SCST-R; Vauth et al., 2004) as a com-
puterized measure of social schema.
Statistical Analyses
All analyses were conducted using SPSS 24.0 (SPSS Inc., Chicago,
IL). Raw data were checked for normality and outliers. Group compar-
isons between INT and TAU as well as between completers and
noncompleters of therapy at baseline were performed using chi-square
analyses and t-tests. With regard to therapy outcomes, the intent-to-treat
analysis was based on a repeated measures General Linear Model
(GLM) for two (2 2) and three assessment points (2 3). Pearson cor-
relation coefficients were used to detect associations between negative
symptoms and other areas of functioning. However, a power analysis at
TABLE 1. Patient Characteristics (N = 58)
INT (n = 32) TAU (n = 26)
M (SD) M (SD) t/χ2 p
Age at baseline, y 32.1 (9.1) 31.5 (7.7) 0.3 0.76
Age at first episode, y 24.3 (7.2) 22.7 (6.8) 0.9 0.38
Duration of illness, y 7.4 (5.9) 8.8 (5.6) 0.9 0.35
No. hospitalizations 3.9 (3.3) 3.7 (4.1) 0.3 0.79
IQ (WAIS-R) 107.7 (9.6) 106.3 (12.0) 0.5 0.65
Education, y 12.5 (2.6) 12.7 (3.1) 0.3 0.79
Symptom sum score (PANSS) 53.3 (10.6) 55.2 (10.2) 0.7 0.49
GAF 53.4 (8.0) 55.4 (8.5) 0.9 0.36
Medication (chlorpromazine equivalent dose) 307.2 (259.9) 371.6 (308.0) 0.8 0.45
Sex (% male) 56.3 61.5 0.2 0.68
WAIS-R, Reduced Wechsler Intelligence Test (WIP, Dahl, 1986); PANSS (Kay et al., 1987); GAF (DSM-4); t, t-tests for normally distributed variables; χ2, χ2 tests
for categorical variables.
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an alpha level significance of 5% suggested that the study sample size fits
only to detect large effects in chi-square, t-tests, Spearman coefficients,
binary logistic regression, and medium effects in GLM with repeated
measures (Cohen, 1988). Following recent recommendations, we also fo-
cused on effect sizes (Nakagawa, 2004). Cohen's d was calculated at
posttherapy and follow-up using the difference of the respective group
means divided by their pooled standard deviation (Cohen, 1988;
Rustenbach, 2003). Cohen's d can be categorized into small (0.2), me-
dium (0.5), and large (0.8) effects.
RESULTS
INT and TAU did not differ significantly in demographic vari-
ables, antipsychotic medication, or in any outcome variable at baseline
(t56 < 1.7, p > 0.09) (Table 1). All patients were taking antipsychotic
medication. Patients assigned to the INT group attended an average
of 81.8% (SD = 9.8%) of therapy sessions.
Relapse Rate
Of the 32 INT patients, 13.3% relapsed in INT group during
therapy, according RSWG criteria addressing PANSS (Andreasen
et al., 2005). This was significatly less compared with 13 of the 26 con-
trol patients under TAU conditions (Fig. 2). Transformed into effect
size, this relationship comprises Cohen's d = 0.80, which represents a
high effect. During the 9-month follow-up, the INT group displayed
nearly half of the relapse rate (24.1%) as the TAU group (53.8%);
d = 0.63. Including dropped-out patients as from whom no further data
were available at follow-up and defining them as relapsed, the superior-
ity of INT regarding relapses is still significantly lower (χ2 = 4.2;
p < 0.04; d = 0.54) compared with controls.
Symptoms, Antipsychotic Medication, and
Functioning Outcomes
Symptom responsewas operationalized using the RSWGcriteria
(Andreasen et al., 2005), which are based on eight PANSS items. The
change of symptom severity over the three assessment points in these
items has been analyzed using a GLM for repeated measures. From
these variables, the INT group had significantly lower symptoms of
passive social withdrawal than TAU at both posttreatment and follow-
up (Table 2). The INT group also had significantly lower symptoms
of “delusions” and “unusual thought content” as measured by the
PANSS positive and general subscales at posttreatment but not
follow-up. Finally, INT showed significant improvements in negative
and general symptoms as well as in the total PANSS score; however,
there were no significant differences in positive symptoms between
INT and TAU groups.
The mean dose of antipsychotic medication was relatively stable
over the assessment period of 1 year. GLMmodeling including all three
assessment points showed no interaction effect (F = 0.34; p = nonsignif-
icant); however, there was a trend for time (F = 2.4; p = 0.09).
The INT group had significant improvements in functioning as
assessed by the GAF. Regarding cognition, the only significant changes
found were in speed of processing and social schema. There were no
significant differences between groups in attention, memory, and verbal
workingmemory. The INT group had superior effects during therapy in
problem solving, but at follow-up, patients under the TAU condition
improved strongly in this domain. Lastly, the INT group was better able
to recognize the intensity of the perceived emotion (EMOREG) both at
posttreatment and follow-up, but there were no differences in accuracy
of identifying the emotions (PFA) (see Table 2).
Many of these very stable patients with schizophrenia or
schizoaffective disorder showed relatively high cognitive functioning
in most of the assessed cognitive domains at baseline, which reduced
the range of improvement. We analyzed the cognitive profile of each
participant at baseline and extrapolated the neurocognitive measures
that fell below the 10th percentile of the standardized test score for each
participant so that each participant's profile had at least one severe def-
icit represented in their profile. This was represented in the average
neurocognitive deficit (AND) score for each participant. Because no
standard values were available for most of the used social cognitive
measures, a social cognitive composite (SCC) score representing the
mean of the standardized raw data of the three measures in that cogni-
tive area was also created. Finally, we created a global measure of out-
come called the proximal outcome mean (POM) score, which includes
both AND score and SCC scores for each participant. All three cogni-
tive scores were significant during therapy and at follow-up favoring
INT compared with TAU (Table 2).
Factors Associated With Relapse
We calculated a binary logistic regression analysis to control for
factors associated with the treatment, patient characteristics, level of
cognitive and social functioning, or severity of symptoms and relapse.
For that purpose, we first pooled the two comparison groups INT and
TAU and correlated the patient characteristics, treatment condition,
PANSS symptom scores, three cognitive scores (AND, SCC, POM),
and the GAF score after treatment with patients' respective relapse sta-
tus using Spearman's rho. We included the outcome variables assessed
after treatment for two reasons: 1) the randomization procedure allows
FIGURE 2. Rates of stable outpatients matching remission criteria in INT and TAU group during therapy and follow-up.
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for homogeneous comparison groups at baseline. This allows us to at-
tribute group differences after treatment to the intervention; 2) we were
interested in examining the effects of the treatment impact, which is
strongest after therapy. None of the patient characteristic variables cor-
related significantly with the relapse status at posttreatment (r < 0.15;
p = nonsignificant). Relapse status after treatment, however, correlated
with the treatment condition, GAF score, PANSS negative and positive
symptoms (r > 0.39), and a significant correlation with the POM score
representing the proximal cognitive outcome of the experimental group
(r = 0.30). All of the variables that correlated with relapse status were
included in the logistic regression model as covariates. Medication
was also included in the model because of the time effect trend over
the three assessments noted previously. The overall model was highly
significant (χ2 = 35.4; p < 0.01). The model declared R2 = 69% of
the variance and identified 87%of the relapse andmaintained remission
status respectively. Thereby, negative symptoms (χ2 = 6.1; p = 0.02)
and treatment condition (χ2 = 3.5; p = 0.05) had by far the largest im-
pact on relapse. The POM score (χ2 = 2.1; p = nonsignificant) had a
marginal impact; antipsychotic medication and positive symptoms
had no impact (χ2 < 1.5; p = nonsignificant).
DISCUSSION
The main objective of this randomized controlled trial (RCT)
study was to evaluate the efficacy of INT for relapse prevention in sta-
bilized outpatients with schizophrenia. For this purpose, we operation-
alized relapse according to the RSWG (Andreasen et al., 2005) criteria
using the PANSS assessment. As expected, the INT intervention signif-
icantly reduced relapses compared with the TAU condition where only
13.3% of participants relapsed in the INT group during therapy com-
pared with 50% of participants in the TAU group. The relapse rate of
the INT group increased to 24.1% during follow-up of 12 months com-
pared with 53.8% under TAU. Furthermore, when including the partic-
ipants who dropped out as relapses into the analysis, the favorable
effects supporting INT were maintained. This result was determined
by the very low 1-year study dropout rate of only 10.3%, which also
suggests high acceptance and feasibility of INT implementation in
schizophrenia outpatients. These positive results regarding relapses
are similar to meta-analyses using psychoeducation or family interven-
tions for relapse prevention (Lincoln et al., 2007; Pharoah et al., 2010;
Xia et al., 2011). It should be noted, however, that the relatively high re-
lapse rate observed in the TAU group is surprising and is not related to
differences in patient variables due to no differences found at baseline
between groups. That said, a study conducted by Tao et al. (2015) using
CR also reported a relapse rate of 41% for the TAU condition, indicat-
ing that relapse rates can be relatively high in some patient samples.
Upon examination of the patient's symptom scores, it appears
that the initial symptom scores assessed by PANSS were very low at
study intake. Due to the low symptoms at baseline, there was limited
range for improvement. The goal of INTwas to maintain the low symp-
tom level in the stabilized patient population.We observed some effects
that had favored the INT condition. These resaults are contradictory to a
previous study that examined the effects of INTon symptom remission:
patients in the INT condition showed a significant reduction in positive
symptoms after therapy compared with TAU (Mueller et al., 2015). In-
deed, previous studies have also shown large effect sizes for reductions
in positive symptoms using integrated psychological therpy, which is an
intervention that combines both CR and SST (Roder et al., 2010;
Mueller et al., 2013): other meta-analyses focusing on CR more gener-
ally provide support for relatively small effects in the reduction of positive
symptoms (Revell et al., 2015; Wykes et al., 2011). Regarding negative
symptoms, CR seems to have some effects (Cella et al., 2017) as does
INT in outpatients suffering from severe negative symptoms (Mueller
et al., 2017).
CR treatment using INT strongly improved the reported function-
ing of participants, as assessed by the GAF during therapy as well as at
follow-up. This increased functioning is a common and robust outcome
of studies using INT (Mueller et al., 2015, 2017). Due to the fact that
INT does not include exercises focusing on social functioning, this im-
provement represents a generalization effect. These results are in linewith
meta-analyses examining the effects of CR on functioning (McGurk
et al., 2007; Wykes et al., 2011), where such generalization effects were
only reported in studies using CR approaches that combine different ther-
apeutic techniques rather than focus on neurocognition alone.
Contrary to our expectations, we did not initially find many im-
provements in the neurocognition and social cognition domains. This
paucity of findings could have been due to many of our patients having
minimal symptoms at baseline and did not have many cognitive defi-
cits. This could explain why INTworked only on some of the cognitive
domains. Once we calculated the AND score, which represents the
mean of all assessed neurocognitive impairments that ranged within
the lowest 10% for each participant (individual profile of each patient
with their impaired cognitive domains), we found significantly higher
perfomance of INT patients compared with TAU posttreatment and at
follow-up. The same effect could be found after averaging all assessed
social cognitive scores to an SCC score. The combination of the two
cognitive scores AND and SCC to a POM score was significant after
therapy and at follow-up too. That said, because the POM combines
cognitive domains that may belong to two different and distinct con-
cepts of cognition related in different ways to functional outcome
(Hoe et al., 2012), the results should be interpreted with caution. On
the other hand, the POM score represents a simple and global measure
of proximal outcomewithin INT intervention even in this population of
very stable outpatients. These positive effects of AND, SCC, and POM
are in linewith the results of meta-analysis on CR (McGurk et al., 2007;
Wykes et al., 2011).
Decreases in relapse rates in INT patients compared with con-
trols were also associated with reductions in negative and general symp-
toms, as well as improvements in functioning (GAF) and the cognitive
POM score as depicted in the correlation analyses. The regression anal-
ysis showed that the INT treatment and level of negative symptoms and,
to a lower extent/level, also the POM score after treatment had the
highest impact on relapse during the treatment period. These results
suggest that the daily dose of medication and positive symptoms did
not have a strong impact on relapses. It should be noted that the statis-
tical power was low and therefore reduced its validity. This may explain
why our findings are inconsistent with other studies that found discon-
tinuation of medication or antipsychotic agents to be a strong indicator
of relapses in individuals with schizophrenia (Alphs et al., 2016;
Bowtell et al., 2018b; Kishimoto et al., 2013). Such studies found that
the duration of illness and symptom increases were also identified as
relapse predictors. A recent quantitative review on predictors of con-
tinuing remission or relapse after discontinuation of antipsychotic med-
ication (Bowtell et al., 2018a) indicated that negative symptoms were
identified as predictor of relapses in the early course of schizophrenia
illness. This is in line with previously published findings showing that
INT reduces negative symptoms to a clinically relevant level of remis-
sion (Mueller et al., 2017).
The procedures specific to INT should be taken into consider-
ation when examining the reduced relapse rates. First, INT represents
an integrated CR approach that combines interventions on neurocognition
and social cognition. Today, there is sufficient data available supporting
evidence for CR for proximal outcomes. In addition, there is some ev-
idence that integrated CR approaches are more successful to support
functional outcomes compared with neurocognitive remediation alone
(McGurk et al., 2007; Wykes et al., 2011; Revell et al., 2015). More-
over, previous studies found that INT supported symptom remission
of severe negative symptoms (Mueller et al., 2017). Second, By taking
individual cognitive experiences in the daily life into consideration, the
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INT group therapy may support distal outcome of functioning and
symptoms (such as generalization and transfer effects; Mueller et al.,
2015; Roder et al., 2010). Throughout the intervention, patients learn
to recognize the impact of cognition on coping strategies. Third, there-
fore, the inclusion of tools for emotion regulation and stress reduction
in INT comparable to common behavioral psychoeducation programs
may provide participants with coping strategies that reduce relapses
(Pharoah et al., 2010). Taken together, participants may have learned
to choose helpful coping strategies taught in the treatment to compensate
for their cognitive deficits and to reduce emotional strain in real-life situ-
ations. Besides the INT specific effects, some unspecific therapy effects
may have also had an impact on the relapse rates. First, INT interventions
are conducted in a group setting, which ultimately generates supporting
interactions among patients and therapists. A precondition for successful
group processes in CR procedures also seems to rely on the therapeutic
alliance built between the patients and therapist (Cella and Wykes,
2019). Moreover, good therapeutic alliance is linked with higher medica-
tion compliance (Higashi et al., 2013) and better adherence (Velligan
et al., 2009), which could ultimately impact the relapse rates. The thera-
peutic relationship is one of the key challenges in INT training due to the
different levels of group processes and therapeutic structuring (Roder and
Mueller, 2015). Second, there is some evidence that the use of strategies
to maintain treatment gains may be associated with better therapeutic al-
liance (Cella and Wykes, 2019; McGurk et al., 2007; Roder et al., 2011;
Wykes et al., 2011). INT is based on strategy learning as well as on drill
and practice tasks. Third, the low dropout rate during INT intervention
(6.7%) and the high attendance rate (81.8%), which was homogeneous
across participants (SD = 9.8%), suggest a high acceptance, motivation,
and feasibility of INT in stabilized schizophrenia outpatients.
In summary, our results support the notion that INT reduces re-
lapses. This may be due to improvements seen in cognition, functional
outcome, and symptoms resulting from training specific to neurocogni-
tive, social cognitive, emotion regulation, and stress reduction domains
throughout the treatment. Unspecific therapy factors such as group set-
ting and therapeutic alliance may have also had an additional impact.
That said, these mechanisms need to be further investigated to provide
evidence. The results of this study also point to the possibility that there
may be individual differences in treatment outcome based on the cogni-
tive profile of the patient; however, more evidence is needed to address
this question. Moreover, this study also demonstrated that negative
symptoms have an impact on relapse. This result corroborated the im-
portance of taking negative symptoms into consideration within psy-
chosocial treatment such as CR.
There are some limitations to this study regarding patient selec-
tion and methodological rigor. First, our sample of only well-stabilized
outpatients according to RSWG criteria may undermine the validity of
some results that may not be generalizable to other patient populations
in psychiatric care. Regarding the generalization of the results, it should
also be considered that the relapse rate of the controls was relatively
high, especially during the treatment phase. The strict use of RSWG
criteria for relapse definition seems to be one way of measuring relapses.
Others such as rehospitalization or increases in the level of psychiatric
care may lead to different results. To date, no consensus has been found
regarding relapse definition (Csernansky et al., 2002; Leucht, 2014;
Olivares et al., 2013). Second, relapses according to RSWG criteria were
based on the PANSS assessments after therapy and at follow-up. How-
ever, the PANSS assessment takes a 2-week time frame into account.
As such, it might be possible that some patients suffered from increased
symptoms during the limited time between assessments, which was not
captured by our study. An additional assessment capturing longer periods
would have closed this gap. Third, the GAF scale was administered as a
measure of functional outcome. Although it is widely used and seems ap-
propriate in samples of stable patients, it is confounded with symptom se-
verity and may not be very sensitive for psychosocial changes (Startup
et al., 2002; Robertson et al., 2013). It would have been useful to include
more measures of this domain. Fourth, we did not include measures
assessing therapeutic ingredients such as therapeutic alliance defined
by Cella and Wykes (2019). Fifth, patients in the TAU condition did
not receive the same amount of treatment as INT patients, which might
have accounted for some of the differences in the outcome (i.e., relapses
and functioning). Becausewe did not include an active control group, the
impact of the time and attention provided by the INT facilitators could
not be controlled for. Sixth, because of the relatively small sample size,
wewere only able to describe the potential mechanisms of change related
to relapses rather than using statistical analyses such as structural equita-
tion modeling to determine this mechanism. Seventh, we do not know
any study investigating on the impact of group therapy in schizophrenia
patients on the mechanism of change or relapses.
Overall, this study is one of the first providing evidence that CR
approaches similar to INT in combination with antipsychotic medica-
tion may prevent relapses in schizophrenia outpatients during a 1-year
observation period. Future studies are still needed to assess longer
follow-up periods to determine the long-term effects of CR interven-
tions. Future studies could use larger sample sizes, active comparison
conditions, and more adequate test batteries. They could also include
a more heterogeneous sample that could be prospectively observed over
a longer period.
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